Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- Resource Type
- Article
- Source
- In
Annals of Oncology September 2010 21(9):1804-1809 - Subject
- Language
- ISSN
- 0923-7534